# US 2024/0350646 A1 · Methods and compositions for delivery to and across the blood brain barrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0350646 A1
- Document ID: US20240350646A1
- Status: Published application
- Kind: A1
- Application number: 18/683,871
- Filed: 2022-08-19
- Published: 2024-10-24
- Earliest claimed: 2021-08-20
- Assignees: NUtech Ventures
- Applicants: NUtech Ventures
- Inventors: Forrest KIEVIT; Alex VECCHIO; Sourav ROY; Badrul Alam BONY; Aria TARUDJI; Punita DHAWAN; Saiprasad GOWRIKUMAR
- Web page: https://patentgrep.com/patent/US20240350646A1

## CPC

- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 49/186: {the organic macromolecular compound being polyethyleneglycol [PEG]}
- A61K 49/1866: {the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Described herein are nanoparticle compositions that can be used to target specific regions of the blood brain barrier (BBB). Such nanoparticle compositions can be used to deliver therapeutics to or across the BBB or to image the BBB or the permeability thereof.

## Claims

### Claim 1

A nanoparticle comprising a claudin or occludin polypeptide or portion thereof conjugated thereto, wherein the nanoparticle carries a payload.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein the claudin polypeptide is selected from claudin-1, claudin-3, claudin-5, claudin-11, claudin-12, claudin-25, and claudin-27.

### Claim 3 (depends on 1)

The nanoparticle of claim 1, wherein the claudin polypeptide is claudin-1.

### Claim 4 (depends on 3)

The nanoparticle of claim 3, wherein the claudin-1 polypeptide has the amino acid sequence shown in SEQ ID NO:2.

### Claim 5 (depends on 4)

The nanoparticle of claim 4, wherein the portion of the claudin-1 polypeptide is selected from Cldn146 (SEQ ID NO:3) or Cldn53 (SEQ ID NO:4).

### Claim 6 (depends on 1)

The nanoparticle of claim 1, wherein the payload is an imaging agent.

### Claim 7 (depends on 6)

The nanoparticle of claim 6, wherein the imaging agent is Gd.

### Claim 8 (depends on 6)

The nanoparticle of claim 6, wherein the imaging agent is a radiotracer.

### Claim 9 (depends on 1)

The nanoparticle of claim 1, wherein the payload is a therapeutic agent.

### Claim 10 (depends on 9)

The nanoparticle of claim 9, wherein the therapeutic agent is a bispecific antibody, a monoclonal antibody, an immunoglobulin fragment, an immunotoxin, a nucleic acid, a protein (e.g., a recombinant protein), a drug, a small molecule, a pharmaceutical, or combinations thereof.

### Claim 11 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle is an ultrasmall nanoparticle.

### Claim 12 (depends on 1)

The nanoparticle of claim 1, wherein the nanoparticle is about 3.5 nm in diameter.

### Claim 13 (depends on 1)

The nanoparticle of claim 1, wherein the NPs are coated with PEG diacid.

### Claim 14 (depends on 1)

A method of delivering a therapeutic to or across the blood brain barrier (BBB) in an individual, comprising:
delivering the nanoparticle of claim 1 to the individual, wherein the payload is a therapeutic.

### Claim 15 (depends on 1)

A method of imaging the blood brain barrier or determining the permeability of the blood brain barrier in an individual, comprising:
administering the nanoparticle of claim 1 to the individual, wherein the payload is an imaging agent.

### Claim 16 (depends on 14)

The method of claim 14, wherein the individual is experiencing neurocognitive decline.

### Claim 17 (depends on 14)

The method of claim 14, wherein the individual is at risk of experiencing neurocognitive decline.

### Claim 18 (depends on 14)

The method of claim 14, wherein the individual has or has had a brain tumor.

### Claim 19 (depends on 14)

The method of claim 14, wherein the individual has or has had a traumatic brain injury (TBI).

### Claim 20 (depends on 14)

The method of claim 14, wherein the individual has been diagnosed with a neurological disorder.

### Claim 21 (depends on 20)

The method of claim 20, wherein the neurological disorder is Alzheimer's disease.

### Claim 22 (depends on 14)

The method of claim 14, wherein the administering step is via oral administration.
